Home › Compare › MSCC vs MRK

MSCC vs MRK: Dividend Comparison 2026

MSCC yields 2.91% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $6.7K in total portfolio value
10 years
MSCC
MSCC
● Live price
2.91%
Share price
$68.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.1K
Annual income
$350.97
Full MSCC calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — MSCC vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMSCCMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MSCC + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MSCC pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MSCC
Annual income on $10K today (after 15% tax)
$247.31/yr
After 10yr DRIP, annual income (after tax)
$298.32/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $509.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MSCC + MRK for your $10,000?

MSCC: 50%MRK: 50%
100% MRK50/50100% MSCC
Portfolio after 10yr
$27.4K
Annual income
$650.63/yr
Blended yield
2.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MSCC
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MSCC buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMSCCMRK
Forward yield2.91%3.25% ✓
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$24.1K$30.7K ✓
Annual income after 10y$350.97$950.29 ✓
Total dividends collected$3.2K$6.1K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MSCC vs MRK ($10,000, DRIP)

YearMSCC PortfolioMSCC Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,991$290.95$11,192$351.54$201.00 → MRK
2$12,059$298.86$12,524$392.70$465.00 → MRK
3$13,210$306.46$14,015$438.65$805.00 → MRK
4$14,448$313.74$15,682$489.96$1.2K → MRK
5$15,780$320.70$17,547$547.23$1.8K → MRK
6$17,212$327.35$19,632$611.16$2.4K → MRK
7$18,751$333.70$21,963$682.53$3.2K → MRK
8$20,403$339.75$24,571$762.18$4.2K → MRK
9$22,177$345.50$27,486$851.08$5.3K → MRK
10$24,080$350.97$30,745$950.29$6.7K → MRK

MSCC vs MRK: Complete Analysis 2026

MSCC — Stock

MSCC is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in MSCC shares.

Full MSCC Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this MSCC vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MSCC vs SCHDMSCC vs JEPIMSCC vs OMSCC vs KOMSCC vs MAINMSCC vs JNJMSCC vs ABBVMSCC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.